Position paper on medication-related osteonecrosis of the jaw (MRONJ)

It is now 12 years since the first article on medication-related osteonecrosis of the jaw (MRONJ) was reported in 2003. The recognition of MRONJ is still inconsistent between physicians and dentists but it is without doubt a severe disease with impairment of oral health-related quality of life. This...

Full description

Saved in:
Bibliographic Details
Published in:Wiener medizinische Wochenschrift 2016-02, Vol.166 (1-2), p.68-74
Main Authors: Svejda, B, Muschitz, Ch, Gruber, R, Brandtner, Ch, Svejda, Ch, Gasser, R W, Santler, G, Dimai, H P
Format: Article
Language:ger
Subjects:
Bevacizumab - adverse effects
Bevacizumab - therapeutic use
Bisphosphonate-Associated Osteonecrosis of the Jaw - diagnosis
Bisphosphonate-Associated Osteonecrosis of the Jaw - prevention & control
Bisphosphonate-Associated Osteonecrosis of the Jaw - therapy
Bone Density Conservation Agents - adverse effects
Bone Density Conservation Agents - therapeutic use
Bone Neoplasms - drug therapy
Bone Neoplasms - secondary
Denosumab - adverse effects
Denosumab - therapeutic use
Diphosphonates - adverse effects
Diphosphonates - therapeutic use
Dose-Response Relationship, Drug
Risk Factors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:It is now 12 years since the first article on medication-related osteonecrosis of the jaw (MRONJ) was reported in 2003. The recognition of MRONJ is still inconsistent between physicians and dentists but it is without doubt a severe disease with impairment of oral health-related quality of life. This position paper was developed by three Austrian societies for dentists, oral surgeons and osteologists involved in this topic. This update contains amendments on the incidence, pathophysiology, diagnosis, staging and treatment and provides recommendations for management based on a multidisciplinary international consensus. The MRONJ can be a medication-related side effect of treatment of malignant and benign bone diseases with bisphosphonates (Bp), bevacizumab and denosumab (Dmab) as antiresorptive therapy. The incidence of MRONJ is highest in the oncology patient population (range 1-15 %), where high doses of these medications are used at frequent intervals. In the osteoporosis patient population, the incidence of MRONJ is estimated to be 0.001-0.01 %, marginally higher than the incidence in the general population (
ISSN:1563-258X
DOI:10.1007/s10354-016-0437-2